Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease

BACKGROUND: High inter‐individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine‐induced myelosuppression, thiopurine‐induced pancreatitis and immunogenicity of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aliment Pharmacol Ther
Autors principals: Bangma, Amber, Voskuil, Michiel D., Uniken Venema, Werna T. C., Brugge, Harm, Hu, Shixian, Lanting, Pauline, Franke, Lude, Dijkstra, Gerard, Festen, Eleonora A. M., Weersma, Rinse K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Efficacy of a Pharmacogenetic Passport for Inflammatory Bowel Disease
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318341/
https://ncbi.nlm.nih.gov/pubmed/32363635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15762
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars